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Objective: To study the elimination of teicoplanin during plasma exchange, a procedure currently used to treat a 
variety of disorders involving immune complexes. Teicoplanin is a glycopeptide antibiotic that exhibits a long terminal 
half-life (100-150 h) and is highly bound to  plasma proteins (unbound fraction (f,)=0.2). 
Methods: Twelve adults with systemic polyarteritis nodosa, cryoglobulinemia-induced vasculitis or dysglobulinemic 
neuropathy undergoing plasma exchange were studied. Each patient received intravenous teicoplanin, 6 mg/kg body 
weight, immediately before plasma exchange. Plasma was assayed for teicoplanin by high-pressure liquid chroma- 
tography. 
Results: A high level of protein binding of teicoplanin was measured within this patient population (98%). The mean 
quantity of teicoplanin eliminated (2SD) was 74.6234.6 mg. The mean drug fraction eliminated by plasma exchange 
(?SD) was 19.5?5.6%. Mean fu value as determined by ultrafiltration (2SD) was 2.221.7%. 
Conclusions: These results show that plasma exchange influences teicoplanin pharmacokinetics, with a clinically 
significant quantity being eliminated. If trough teicoplanin concentrations of around 10 mg/L are desired, it is 
recommended that teicoplanin dosage be supplemented or given after plasma exchange. 
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INTRODUCTION 
Plasma exchange is primarily used to treat systemic 
diseases, notably those of autoimmune origin. This 
technique rapidly gained popularity due to the 
development during the early 1980s of simple and 
effective technology that could simultaneously remove 
and replace plasma volume for volume. In the light of 
the capacity of this procedure to extract endogenous as 
well as xenobiotic molecules, it is essential to under- 
stand the pharmacokinetic modifications that plasma 
exchange may induce upon medication prescribed to 
these patients [lj.  
Several studies have investigated two classes of 
antibiotics, namely aminoglycosides and p-lactams. 
Two studies concerned the former: Yakatan et al [2j 
showed that <3% of a dose of kanamycin was elimin- 
ated during a plasma exchange session, whereas Prince 
et al [3] reported a 35% decrease in plasma concen- 
tration of gentamicin compared to the initial level in 
newborns. p-lactam elimination during plasma ex- 
change has been the subject of four investigations: 
Prince et a1 [3] found that circulating ampicillin con- 
centrations dropped by 35%; Bozkurt et al [l] noted 
that ceftazidime elimination varied from 2% to 9% 
depending on whether the patient had renal insuffic- 
iency; and Bakken et al [4j and Fauvelle et a1 [S] 
observed that the fraction of ceftriaxone eliminated 
reached 6-12% and 11.5-24% respectively, depending 
upon the time lapse between drug administration and 
the onset of plasma exchange. The influence of plasma 
exchange on the elimination of glycopeptides is un- 
known. 
Teicoplanin is a glycopeptide antibiotic active 
against Gram-positive bacteria. The therapeutic range 
when teicoplanin is measured by liquid chronia- 
tography is 10-20 mg/L (trough concentration at 
equilibrium), except in bacterial endocarditis, where a 
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level of 20-25 mg/L is recommended [6]. When 
teicoplanin levels are measured by microbial assay, the 
optimal range is 25% higher (manufacturer's recom- 
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mendation, Marion Merrell S.A., Puteaux, France). 
Teicoplanin has a very long terminal ha-life (1 00-1 50 
h), a volume of distribution ( V d )  at a steady state of 
0.8-1.6 L/kg, and high protein binding of >90%. 
Extracorporeal elimination can be calculated from 
the fraction of drug removed (fe) during a session of 
plasma exchange. In this study we have evaluated the 
removal of teicoplanin during plasma exchange and 
describe the relationship between f’d, plasma protein 
binding and& in the removed volume of plasma. 
MATERIALS AND METHODS 
Patient selection 
Twelve adults treated with multiple episodes of plasma 
exchange participated in the study (five men and seven 
women; mean agekstandard deviation (SD) 602  13 
years, mean weight (kSD) 63.2222.7 kg, mean serum 
creatinine (2SD) 75.9+19.6 pmol/L). The patients 
suffered from polyarteritis nodosa (PAN), cryoglobul- 
inemia-induced vasculitis or dysglobulinemic neuro- 
pathy. AU patients with PAN had pathologic evidence 
of necrotizing vasculitis. Patients on hemodialysis, 
patients with known glycopeptide allergy and preg- 
nant women were excluded. The study protocol was 
approved by the Biomedical Ethics Committee of the 
Groupe Hospitalier Piti&Salp&ri&re. Informed consent 
was obtained from each patient included in the study. 
Teicoplanin administration 
Immediately before plasma exchange, each patient 
received teicoplanin (Targocid, Marion Merrell S.A.) at 
a dose of 6 mg/kg body weight intravenously via a 
forearm vein over 1 min. This was performed on day 4 
of plasma exchange therapy. 
Blood samples 
Blood samples were collected in tubes without anti- 
coagulant prior to and 5 min after the administration 
of teicoplanin, at the start, middle and end of the plasma 
exchange procedure, and at 4, 6, 8, 12 and 24h 
following the teicoplanin injection. After centrifug- 
ation and separation, sera were stored at -20°C until 
analysis. An aliquot of the total volume of plasma 
eliminated during plasma exchange was stored at 
-20°C. 
Plasma exchange protocol 
Each session began immediately after the administra- 
tion of teicoplanin. Plasma exchange was performed 
with a continuous-flow centrifugation system (IBM 
2297 cell separator). Each plasma exchange removed 
60 mL plasma/kg (total 2660-5486 mL). To restore 
plasma volume, a replacement solution consisting of 
4% human albumin and 500mL gelatin was infused 
intravenously throughout the procedure. To ensure 
anticoagulation, citrate (pH 5.050.5) was given in a 
1 : l O  v/v ratio with blood. Citrate has no effect on the 
protein binding of drugs [ 5 ] .  Every patient underwent 
14 sessions of plasma exchange over 3 weeks, and 
hemostasis was assessed before and after each session. 
Teicoplanin assay 
Teicoplanin levels were measured using HPLC according 
to the method of Jehl et al 171. The limit of the 
quantification of the assay was 1 mg/L and the between- 
run coefficient of variation (CV) varied from 11.5% at 
3 mg/L to 7.4% at 120 mg/L. Results are expressed as 
total teicoplanin, but only the main component (A2-2) 
is measured in this assay. 
Protein binding 
The unbound fraction cfu) of teicoplanin in serum was 
measured by using Microsep units (Filtron Technology 
Corporation, Northborough, UK). Each sample (1mL) 
was placed in a Microsep unit (cut-off 10 000 D) and 
was centrifuged at 3000 rev/min for 60 min at 37°C. 
The ultrafiltrate was collected and 100-p.L aliquots were 
injected into an HPLC column. Thef, was calculated 
using the following formula: J;=l/(NK),+ 1 with 
(NK)p=(Cp/Cu)-l, where N is the concentration 
of binding sites per molecule, K is the association 
constant, C, is the concentration of teicoplanin in the 
plasma before centrifugation, and C, is the concen- 
tration of teicoplanin in the ultrafiltrate. 
Some investigators have reported low non-specific 
binding of teicoplanin to the ultrafiltrate unit mem- 
brane. This problem was addressed by preparing 
aqueous standards of teicoplanin (20.7 mg/L, n=5).  
These were also placed in the Microsep units as 
described above and the resulting ultrafiltrates analyzed 
to calculate the non-specific bindmg of teicoplanin 
(NK)Ns to the unit. The mean value of (NK)Ns was 
0.52. The& was corrected by subtracting (NK)Ns from 
(NK), in the equation described above. 
Pharmacokinetic analysis 
The elimination of teicoplanin by plasma exchange was 
determined by the amount of drug removed (@E) as 
follows: Q~E=CPEX V&, where CPE is the concentra- 
tion of teicoplanin in the removed volume VPE. The 
drug fraction eliminated during each exchange (fe) can 
be estimated by the equation fe (%)=&/dose of 
teicoplanin administered. The index of drug extraction 
(%) is calculated as follows: 7.5 (l+f,)/Vd; where Vd 
is the volume of distribution of the drug in liters. This 
formula represents, for drugs that bind to albumin, the 
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fraction present in extracellular fluids [8]. For teico- 
planin, I was calculated for the extreme values of I.h 
reported in the literature (0.8 and 1.6 L/kg) multiplied 
by the body weight in kilograms. 
RESULTS 
Table 1 presents the details of the exchange procedure 
and the data concerning the effect of plasma exchange 
on the teicoplanin concentration. The mean (2SD)  
plasma volume removed was 38282855 mL. Figure 1 
shows the mean concentration-time profile of teico- 
planin in serum. The decline in the serum teicoplanin 
level appears to be influenced by plasma exchange. 
Once the plasma exchange session finished, there was 
a rebound in the serum concentration of teicoplanin, 
possibly due to redistribution of drug from tissue to 
the vascular compartment. The mean (2SD)  quantity 
of teicoplanin cleared from the body as the result of 
the exchange procedure was 74.6234.6 mg. The 
mean (+SD)f, was 19.5?5.6%. The mean (2SD)  
concentration of teicoplanin 24 h after administra- 
tion was 2.821.3 (range 0.8-4.8) mg/L. This is a 
consequence of the large I.h of teicoplanin and reflects 
a wide tissue distribution. The individualf, values are 
given in Table 2;  the mean (+SD)f, was 2.2+1.7%. 
Teicoplanin was not detected in the ultrafiltrates of 
three patients. 
Table 1 Quantities of teicoplanin removed by plasma exchange (&) and the drug fraction eliminated (5) 
~~ ~~ 
Patient Dose (mg) Plasma removed (mL) Plasma teicoplanin (mg/L) QPE (mg) j e  (“A) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
MeankSD 
276 
570 
270 
370 
282 
270 
276 
438 
630 
240 
420 
540 
381k 136 
3790 
4800 
3120 
3650 
3230 
3250 
3160 
3640 
5486 
2660 
4290 
4860 
3828k-855 
13.6 
23.7 
22.7 
26.9 
18.7 
15.6 
15.0 
23.4 
14.0 
10.0 
13.8 
31.8 
19.1*6.5 
51.5 
113.8 
70.8 
98.2 
60.4 
50.7 
47.4 
85.2 
76.8 
26.6 
59.2 
154.5 
74.6k34.6 
18.7 
20.0 
26.2 
26.5 
21.4 
18.8 
17.2 
19.5 
12.2 
11.1 
14.1 
28.6 
19.525.6 
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Figure 1 Kmetics of teicoplanin elimination by plasma exchange in 12 patients. The horizontal bar represents the period of 
plasma exchange, and the arrow indicates the time of teicoplanin administration. PE, plasma exchange. 
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Table 2 Concentrations of proteins, unbound fractions of teicoplanin V;) and index predictive of drug extraction (I). 
Total protein Albumin P-Globulin ?-Globulin 
(g/L) (dL)  (g/L) (g/L) 
Patient fu (W I (%) (NR: 58-72) (NR: 33-55) (NR: 6-13) (NR: 7-15) 
1 1.33 1&20 53 30 7.4 6.1 
2 0.84 5-10 58 41 7.1 2.3 
3 ND ND 55 36 8.0 2.7 
4 0.78 8-1 6 51 30 6.4 6.2 
5 0.69 10-20 62 32 9.4 11.9 
6 ND ND 64 28 12.0 12.0 
7 4.4 10.5-2 1 57 27 7.9 13.0 
8 5.8 6.75-14 55 33 5.0 5.7 
9 1.95 4.55-9.1 47 19 8.2 9.3 
10 ND ND 46 25 6.6 6.8 
11 2.05 6.85-13.7 55 38 6.0 2.9 
12 2.1 5.3-10.6 55 39 6.2 1.8 
MeankSD 2.2k1.7 7.45-Cl4.9 
1 (%)=7.5 (l+J)/Li with Ih+0.8 or 1.6 L/kg x body weight in kg. 
ND, not detected; NR, normal range. 
Table 3 Pharmacokinetic parameters of various drug classes during plasma exchange 
Drugs ,L (%) I.2 (L/kg) f“ (%) I (“Yo) References 
Aciclovir 2.5 1.8 85 11 [91 
Ceftriaxone 1 g 23 0.1 4 100 [51 
Ceftriaxone 2 g 12.6 0.2 17 63 [41 
Ceftazidime 2-9 0.25 85 79 [11 
Diclofenac 13.6 0.1 1 98 u51 
Digitoxin 5.5 0.45 10 22 [101 
Hypoxanthine arabinoside 8 0.6 95 35 1151 
Paracetamol 5 1 .o 95 21 ~ 5 1  
Prednisolone 1.0 1.3 10 9 ~ 3 1  
Tobramycin 6.8-10 0.25 90 81 ~ 4 1  
Digoxin 1 .2 6.0 73 3.1 
Phenytoin 4 4  0.55 10 22 [11, 121 
Teicoplanin 20 0.8-1.6 2 7.5-15 This study 
Zidovudine 1 .o 3.0 75 6.0 1151 
~ 
F, amount of drug eliminated; LL, volume of &stribution;f,, unbound fraction of drug; I, index predictive of drug elimination by plasma 
exchange 
Table 3 presents the mean pharmacokinetic para- 
meters of teicoplanin and various drugs bound to 
albumin during plasma exchange [9-141, assuming 
a mean body weight of 63.2 kg for the calculation 
of I. 
DISCUSSION 
The effect ofplasma exchange on the pharmacokinetics 
of teicoplanin has clinical significance because 20% 
(range 11.1-28.6%) of a single dose is removed by the 
exchange procedure. In the light of this effect of plasma 
exchange on serum concentrations of teicoplanin, 
dosage adjustment is required. In our previous studies 
we showed that L2,g [15] and the delay between drug 
administration and plasma exchange [5] were major 
determinants of&. 
Teicoplanin disposition has been described by a tri- 
ponential equation. The half-lives of the first and 
second phases are 20-30 min and 1.6-4 h respectively 
[16]. This three-compartment model showed that, for 
the most part, the distribution phase was completed 
after 4 h. In the study reported here, plasma exchange 
began immediately following teicoplanin administra- 
tion and, at this time, the majority of drug would be in 
the vascular space. Furthermore, the high teicoplanin 
clearance indicates that teicoplanin was available in the 
vascular compartment. If plasma exchange had started 
more than 4 h after teicoplanin administration,& would 
have been lower. Hence, the effect of plasma exchange 
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Figure 2 Relationship between the fraction of a drug 
eliminated during a plasma exchange session (5) and the 
index of drug extraction (I), Data from references [5, 9-15]. 
A Teicoplanin. The lines indicate the range for 1 and 
mean 2 SD forfe. 
W Aciclovir, ceftriaxone (1 g, ?. g), ceftazidime, diclofenac, 
digoxin, digitoxin, hypoxanthine-arabinoside, paracetamol, 
phenytoin, prednisone, tobramycin, zidovudine as drug test. 
on basal teicoplanin at steady state will be negligible 
provided that plasma exchange occurs at the end of the 
dosage interval. 
Kegarding the influence of fu, the present study 
demonstrated very high protein binding of teicoplanin 
(98%). The degree ofprotein binding observed in these 
patients is not in complete agreement with previous 
studies [16-181 and may be due to quantitative or 
qualitative differences in plasma protein concentrations. 
Indeed, serum albumin and total protein concentra- 
tions were below the normal range in eight and nine 
of the 12 patients respectively (Table 2). 
Thus, the high degree of protein binding (98%) 
could explain the strong effect of plasma exchange 
on the pharmacokinetics of teicoplanin. The results 
obtained with ceftriaxone in previous studies are in 
agreement with this hypothesis. Ceftriaxone is 95% 
protein bound, andf, exceeded lo%, 12.6% and 23%, 
in the studies by Bakken et al [4] and Fauvelle et al [5] 
respectively. 
In an earlier study [15], we demonstrated that for 
a drug bound to albumin a relationship exists between 
thef, during plasma exchange and the fraction present 
in the extracellular fluids described by Rowland and 
Tozer's formula: 7.5 ( l + j J / t ' d  [S]. We chose the 
fraction present in the extracellular fluids as an index 
predictive of drug extraction by plasma exchange. 
Figure 2 shows the correlation between mean-fe during 
plasma exchange and the mean index for a number of 
drugs bound to albumin (Table 3) [15]. In contrast, we 
did not find such a correlation for teicoplanin. These 
data suggest that other kinds of drug-protein inter- 
actions are involved with teicoplanin. Indeed, teico- 
planin binds more than one plasma protein, and 
globulins may be an important teicoplanin-binding 
protein in human plasma 1193. 
To conclude, these findings indicate that plasma 
exchange influences teicoplanin disposition owing to 
its high protein binding. Therefore, it is better to 
perform plasma exchange at the end of the teicoplanin 
dosing interval and to administer teicoplanin after 
plasma exchange to ensure its therapeutic efficacy. 
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